Prescription medicine
Travoprost Brand names: Travatan, Idose
Travoprost (Travatan) is a prescription medicine with an FDA approval on record since 2001. FDA's NDC Directory lists it from 11 generic labelers, and pharmacies paid $9.07 per mL (Travoprost 0.004% eye drop) in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
Check it at the source: the travoprost FDA label on DailyMed (effective January 31, 2025, Sandoz Inc); the NDA 21257 record on Drugs@FDA; every travoprost label on DailyMed.
Highlights of the record
FDA label of January 31, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTRAVATAN Z ® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Forms and strengths
- 0.04 mg/ml
Solution/ drops; solution; implant.
On the market
- Earliest approval on file
- March 16, 2001 Travatan, Alcon Pharms Ltd; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 9 first March 1, 2013; 7 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 14 of which 11 under generic applications, 3 under brand applications, repackagers included
- Last listed patent
- October 13, 2029 Travatan Z solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $9.07 per mL Travoprost 0.004% eye drop
- Shortage (FDA)
- None current 2 past records
- Recalls by its makers (FDA)
- 3 since 2016 0 Class I among all firms' recalls; latest May 25, 2023; 1 more by firms not listed as its makers
- FAERS reports
- 8,609 through July 30, 2026
What is travoprost used for?
From the label: indications and usageTRAVATAN Z ® (travoprost ophthalmic solution) 0.004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. TRAVATAN Z is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Conditions named in the indications of travoprost's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Prostaglandin Analog.
Source: FDA drug label (Travatan Z), Sandoz Inc, effective January 31, 2025 (SPL set 4b5cffb0-74e0-44e4-8e18-f5d56e9db450), via openFDA; the full label on DailyMed
Is there a generic for travoprost (Travatan)?
The FDA approved the first generic travoprost on March 1, 2013. 9 generic applications are approved; 7 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists travoprost from 11 labelers under a generic (ANDA) application and from 3 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 3 patents for Travatan Z solution/drops, the last expiring on October 13, 2029; a patent listed only for Idose Tr implant runs to February 14, 2031. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2001 earliest approval on file
- 2013 first generic approved
- 2029 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for travoprost (Travatan)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $9.07 per mL (Travoprost 0.004% eye drop), down 17% from $10.87 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Travoprost 0.004% eye drop (generic)
- Travatan z 0.004% eye drop (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Travoprost 0.004% eye drop | Generic | $9.07 per mL | n/a | -17% |
| Travatan z 0.004% eye drop | Brand | $94.26 per mL | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is travoprost in shortage?
No travoprost presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 2 records are all marked to be discontinued, the latest updated July 7, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | July 7, 2026 |
| Travoprost, Ophthalmic Solution, 0.004%, 5 mL (NDC 0378-9651-50) | Mylan Pharmaceuticals Inc., a Viatris Company | To Be Discontinued | July 7, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has travoprost been recalled?
The FDA's Enforcement Report lists 4 recalls naming travoprost since 2016: 0 Class I (the most serious), 4 Class II, 0 Class III; 0 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of travoprost and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| May 25, 2023 | Class II | Golden State Medical Supply Inc. | Lack of Assurance of Sterility: Tamper Evidence Seal is missing on secondary container. |
| April 1, 2022 | Class II | Mylan Pharmaceuticals Inc | Subpotent Drug and Failed Impurities/Degradation Specifications: low out-of-specification results obtained for assay and high out-of-specification results for … |
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
| October 5, 2016 | Class II | Par Pharmaceutical, Inc. not a listed maker | Lack of Assurance of Sterility; damage to the internal portion of the dropper tip portion of the container |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What do FAERS reports show for travoprost?
The FDA Adverse Event Reporting System holds 8,609 reports that list travoprost among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 330 are coded as a death and 1,134 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2020 (2,609, against a median of 483 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as travoprost?
17 other medicines are given the same way (ophthalmic) and in the same FDA class as travoprost or labeled mainly for the same use (glaucoma), the same class first. Glaucoma lists all 20 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (ophthalmic) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Bimatoprost | Glaucoma | 13 labelers | $6.97 per mL 0.03% eye drops | No current entry |
| Latanoprost | Glaucoma | 14 labelers | $1.58 per mL 0.005% eye drops | No current entry |
| Tafluprost | Glaucoma | 3 labelers | $2.45 per unit 0.0015% eye drop | No current entry |
| Latanoprost and netarsudil | Glaucoma | none listed | $139.40 per mL 0.02%-0.005% eye drp | No current entry |
| Timolol | Glaucoma | 21 labelers | $0.774 per mL 0.5% eye drops | No current entry |
| Brimonidine | Glaucoma | 12 labelers | $9.06 per mL 0.1% drop | No current entry |
| Dorzolamide and timolol | Glaucoma | 14 labelers | $0.893 per mL Dorzolamide-timolol eye drops | No current entry |
| Brimonidine and timolol | Glaucoma | 14 labelers | $2.15 per mL 0.2%-0.5% | No current entry |
Every medicine labeled for the same conditions as travoprost
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does travoprost compare with medicines for the same use?
3 side-by-side pages set travoprost beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to travoprost
- 17 medicines for the same use
- Other prostaglandin analogs
- the pharmacologic class, with prices and generics
- Travoprost side effects
- the label's list beside FAERS reports
- Travoprost shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other